论文部分内容阅读
目的探讨生物制剂益赛普联合甲氨蝶呤治疗类风湿性关节炎的临床效果。方法选择我院2009年-2011年收治的类风湿性关节炎患者76例,随机分成两组各38例,观察组给予益赛普25mg/次,皮下注射,2次/周,口服给予甲氨蝶呤10mg/次,1次/周,疗程为12周;对照组给予口服给予甲氨蝶呤10mg/次,1次/周,疗程为12周。分别于治疗后第6和12周对两组患者进行晨僵持续时间、关节肿胀数、关节触痛数、疼痛程度评价,并对患者治疗后12周红细胞沉降率(ESR)、C反应蛋白(CRP)、类风湿因子(RF)等进行测定和比较。结果观察组治疗12周后除TJC外各项体征和实验室指标均显著好于对照组(P<0.05),观察组在ACR20、ACR50和ACR70方面也显著好于对照组(P<0.05),两组均未发生严重不良反应。结论益赛普联合甲氨蝶呤治疗类风湿性关节炎疗效明显优于单用甲氨蝶呤,但长期疗效及安全性还需进一步观察。
Objective To investigate the clinical efficacy of the combination of Yisuipu and methotrexate in the treatment of rheumatoid arthritis. Methods Sixty-six patients with rheumatoid arthritis who were treated in our hospital from 2009 to 2011 were randomly divided into two groups of 38 patients. The observation group was given 25 mg of ixapine, subcutaneously and twice a week, Pterin 10mg / time, 1 time / week, the course of treatment was 12 weeks; the control group was given methotrexate 10mg / time, 1 time / week for 12 weeks. The duration of morning stiffness, the number of swollen joints, the number of joint tenderness and the degree of pain were evaluated at the 6th and 12th week after the treatment. The ESR, C-reactive protein CRP), rheumatoid factor (RF) were measured and compared. Results All the signs and laboratory indexes except for TJC in observation group were significantly better than those in control group (P <0.05) after 12 weeks of treatment. The observation group was also significantly better than control group in ACR20, ACR50 and ACR70 (P <0.05) No serious adverse reactions occurred in both groups. Conclusion The combination of ibuprofen and methotrexate is superior to methotrexate alone in the treatment of rheumatoid arthritis. However, long-term efficacy and safety need to be further observed.